Bonviva (Ibandronate) injection
Bonviva 3 mg (1 mg/ml) administered as i.v. injection every third month is marketed for the treatment of postmenopausal osteoporosis with the purpose of reducing the risk of vertebral fractures. The documentation is based upon comparison of the response in bone-mineral-density (BMD) to 2,5 mg daily oral ibandronat, which has demonstrated a reduction in vertebral fractions, but not in non-vertebral fractions. Monthly Bonviva 150 mg is recently reviewed by IRF.
The benefit of ibandronat i.v. regimen compared to oral regimes is the avoidance of oral administration comprising low bioavailability, food-interaction and the risk for dyspepsia. The disadvantages include lacking documentation on non-vertebral prophylaxis of fractures, no possibility for self administration, risk of influenza-like symptoms and finally high cost. The primary treatment of choice may still be alendronat. Ibandronat i.v. regimen may be an alternative, if oral treatment is impossible.
Bonviva 3 mg (1 mg/ml) was marketed 22 May 2006.
There is no general reimbursement to Bonviva, but it is possible to apply for individual reimbursement.
- Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis. Arthritis and Rheumatism 2006: 54: 1838-46.
Institute for Rational Pharmacotherapy, 12 June 2006